As AKT inhibitor monotherapy had limited clinical activity in advanced breast cancer patients in part due to inadequate AKT inhibition at tolerable doses62, our study provides a rational for the combination of PRMT5 and AKT inhibitors or chemotherapeutic drugs to achieve better clinical outcomes. Here, PRMT5 is linked to breast cancer.